2,000 Shares in Biogen Inc. (BIIB) Acquired by Lockheed Martin Investment Management Co.
Lockheed Martin Investment Management Co. purchased a new position in Biogen Inc. (NASDAQ:BIIB) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,000 shares of the biotechnology company’s stock, valued at approximately $626,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. bought a new stake in Biogen in the 3rd quarter worth about $123,494,000. Botty Investors LLC grew its stake in shares of Biogen by 75.0% during the 2nd quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock valued at $3,048,000 after purchasing an additional 4,812 shares during the period. BB&T Securities LLC grew its stake in shares of Biogen by 25.0% during the 2nd quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock valued at $3,524,000 after purchasing an additional 2,598 shares during the period. Vanguard Group Inc. grew its stake in shares of Biogen by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock valued at $3,924,258,000 after purchasing an additional 342,568 shares during the period. Finally, Neuberger Berman Group LLC grew its stake in shares of Biogen by 18.6% during the 2nd quarter. Neuberger Berman Group LLC now owns 27,974 shares of the biotechnology company’s stock valued at $7,591,000 after purchasing an additional 4,389 shares during the period. 88.35% of the stock is owned by hedge funds and other institutional investors.
Shares of Biogen Inc. (NASDAQ BIIB) traded up $2.21 on Wednesday, hitting $311.90. The company had a trading volume of 353,483 shares, compared to its average volume of 1,516,820. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46. The stock has a market cap of $65,790.00, a price-to-earnings ratio of 14.62, a P/E/G ratio of 1.97 and a beta of 0.72. Biogen Inc. has a twelve month low of $244.28 and a twelve month high of $348.84.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.70 by $0.61. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the company posted $5.19 earnings per share. The firm’s revenue was up 4.1% compared to the same quarter last year. equities research analysts forecast that Biogen Inc. will post 22.03 EPS for the current year.
WARNING: “2,000 Shares in Biogen Inc. (BIIB) Acquired by Lockheed Martin Investment Management Co.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/15/2000-shares-in-biogen-inc-biib-acquired-by-lockheed-martin-investment-management-co.html.
A number of research analysts recently issued reports on BIIB shares. Deutsche Bank AG reiterated a “buy” rating and set a $319.00 price objective (up from $315.00) on shares of Biogen in a research note on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) raised Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $228.00 to $338.00 in a report on Wednesday, July 26th. BidaskClub raised Biogen from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Vetr raised Biogen from a “hold” rating to a “buy” rating and set a $319.53 price objective on the stock in a report on Monday, July 31st. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Biogen in a report on Thursday, July 27th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $341.89.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.